853921-69-4

Upstream product

• 478132-53-5 [(S)-2-(6-hydroxyindazol-1-yl)-1-methylethyl]carbamic acid benzyl ester 
• 50-00-0 formaldehyd 
• 210580-75-9 AL-34662 
• 501-53-1 benzyl chloroformate 
• 362512-35-4 [(S)-2-(6-Hydroxy-indazol-1-yl)-l-methylethyl]-carbamic acid benzyl ester 
• 23244-88-4 1H-indazol-6-ol 
• 210581-14-9 (R)-1-(6-benzyloxy-indazol-1-yl)-propan-2-ol 
• 874668-62-9 6-(benzyloxy)1-H-indazole 

Downstream Products

• 853921-70-7 [(S)-2-(7-formyl-6-hydroxy-indazol-1-yl)-1-methylethyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma

Novel dioxinoindazole compounds and dioxoloindazole compounds are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions of one

1-((S)-2-aminopropyl)-1H-indazol-6-ol: A potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity

Serotonin 5-HT2 receptor agonists have been identified as a potential new class of agents for the treatment of ocular hypertension and glaucoma. The initially reported tryptamine analogues displayed either poor solution stability, potent centra

SUBSTITUTED FURO[2,3-G] INDAZOLES FOR THE TREATMENT OF GLAUCOMA

Substituted furo[2,3-g]indazoles for lowering intraocular pressure and treating glaucoma are disclosed.